University of South Florida (GVAX vaccine) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

University of South Florida (GVAX vaccine) General Information

Description

CD40LGVAX vaccine to resist lung cancer. The asset includes irradiated allogeneic lung adenocarcinoma cells which are combined with a bystander cell line transfected with hCD40L and hGM-CSF.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • CA
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

University of South Florida (GVAX vaccine) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore University of South Florida (GVAX vaccine)‘s full profile, request access.

Request a free trial

University of South Florida (GVAX vaccine) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore University of South Florida (GVAX vaccine)‘s full profile, request access.

Request a free trial